MORRISVILLE, N.C., Nov. 4, 2010 /PRNewswire/ — Gentris
Corporation (www.gentris.com), a global
leader in applied clinical pharmacogenomics, announced today that
Howard McLeod, Pharm.D., from The University of North Carolina at
Chapel Hill (UNC) has become the Company’s first Chief Scientific
Advisor. Dr. McLeod, an internationally recognized expert in
pharmacogenomics and personalized medicine, is the Fred N. Eshelman
Distinguished Professor and Director of the Institute for
Pharmacogenomics and Individualized Therapy. He holds academic
appointments in the UNC Schools of Pharmacy and Medicine as well as
the Lineberger Comprehensive Cancer Center.
Dr. McLeod is actively involved in global pharmacogenomics
initiatives. He serves as Principal Investigator for the CREATE
Pharmacogenomics Research Network and is a member of the FDA
Committee on Clinical Pharmacology. He is also Vice Chairman for
Pharmacogenomics with the NIH Cancer and Leukemia Group B
Pharmacology and Experimental Therapeutics Committee. As Director
of the PharmacoGenetics for Every Nation Initiative (PGENI), he
works with scientists, medical experts, and government officials
around the world to assist developing countries as they take
advantage of pharmacogenomic innovations to improve decision-making
in the use of biotechnology and pharmaceutical products.
Dr. McLeod has published more than three hundred and eighty
peer-reviewed papers on pharmacogenomics, applied therapeutics, or
clinical pharmacology and serves on the editorial boards of seven
scientific journals. Additionally, he sits on numerous advisory
boards for industry and non-profit organizations.
Gentris Corporation, founded in 2001, is located in the heart of
Research Triangle Park where it provides biotechnology and
pharmaceutical companies with cutting-edge scientific guidance in
patient clinical-trial selection and strategies to reduce adverse
drug reactions. The Company
‘/>”/>
SOURCE